MicroRNA-155 expression is independently predictive of outcome in chordoma

Eiji Osaka; Andrew D. Kelly; Dimitrios Spentzos; Edwin Choy; Xiaoqian Yang; Jacson K. Shen; Pei Yang; Henry J. Mankin; Francis J. Hornicek; Zhenfeng Duan

doi:10.18632/oncotarget.3273

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

MicroRNA-155 expression is independently predictive of outcome in chordoma

Eiji Osaka _, Andrew D. Kelly, Dimitrios Spentzos, Edwin Choy, Xiaoqian Yang, Jacson K. Shen, Pei Yang, Henry J. Mankin, Francis J. Hornicek and Zhenfeng Duan

PDF | HTML | Supplementary Files | How to cite

Oncotarget. 2015; 6:9125-9139. https://doi.org/10.18632/oncotarget.3273

Metrics: PDF 1733 views | HTML 2355 views | ?

Abstract

Eiji Osaka1,2, Andrew D. Kelly3, Dimitrios Spentzos4, Edwin Choy1, Xiaoqian Yang1, Jacson K. Shen1, Pei Yang1, Henry J. Mankin1, Francis J. Hornicek1, Zhenfeng Duan1

1Sarcoma Biology Laboratory, Department of Orthopaedic Surgery, Massachusetts General Hospital, Boston, MA 02114, USA

2Department of Orthopaedic Surgery, Nihon University School of Medicine, Tokyo 173–8610, Japan

3Fels Institute for Cancer Research & Molecular Biology, Temple University School of Medicine, Philadelphia, PA 19140, USA

4Division of Hematology/Oncology, Sarcoma Program, Department of Medicine, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA

Correspondence to:

Zhenfeng Duan, e-mail: [email protected]

Keywords: miRNA-155 (miR-155), chordoma, prognosis, miRNA microarray assay, RT-PCR

Received: November 19, 2014 Accepted: February 07, 2015 Published: March 16, 2015

ABSTRACT

Background: Chordoma pathogenesis remains poorly understood. In this study, we aimed to evaluate the relationships between microRNA-155 (miR-155) expression and the clinicopathological features of chordoma patients, and to evaluate the functional role of miR-155 in chordoma.

Methods: The miRNA expression profiles were analyzed using miRNA microarray assays. Regulatory activity of miR-155 was assessed using bioinformatic tools. miR-155 expression levels were validated by reverse transcription-polymerase chain reaction. The relationships between miR-155 expression and the clinicopathological features of chordoma patients were analyzed. Proliferative, migratory and invasive activities were assessed by MTT, wound healing, and Matrigel invasion assays, respectively.

Results: The miRNA microarray assay revealed miR-155 to be highly expressed and biologically active in chordoma. miR-155 expression in chordoma tissues was significantly elevated, and this expression correlated significantly with disease stage (p = 0.036) and the presence of metastasis (p = 0.035). miR-155 expression also correlated significantly with poor outcomes for chordoma patients (hazard ratio, 5.32; p = 0.045). Inhibition of miR-155 expression suppressed proliferation, and the migratory and invasive activities of chordoma cells.

Conclusions: We have shown miR-155 expression to independently affect prognosis in chordoma. These results collectively indicate that miR-155 expression may serve not only as a prognostic marker, but also as a potential therapeutic target in chordoma.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 3273

Publication Alerts

Research Papers:

MicroRNA-155 expression is independently predictive of outcome in chordoma

Abstract